Historical text by DatBTrue, written between 2008 and 2016 and reproduced verbatim. It records what was argued then; it is not dosing guidance and not medical advice. Read the disclaimer.

Let’s start simply. Hypertrophy results from an enlargement. It is an increase in the size of something that exists and in regard to hypertrophy in skeletal muscle it is simply an increase in the size of existing muscle fibers. Hypertrophy does not refer to an increase in the number of pre-existing muscle fibers. IGF-1 is pro-hypertrophy meaning it promotes hypertrophy. It can play a role in the rare occurrence of hyperplasia which is an increase in the number of pre-existing muscle fibers. However most muscle mass increases in everyone from professional bodybuilders to the weekend hobbiest comes from hypertrophy so much so that hyperplasia is best left out of the anabolic discussion. Most people like the sound of the word “hyperplasia” but it is hypertrophy that does all the heavy lifting.

When free IGF-1 or rather the mature form of IGF-1 binds to it’s receptor it triggers a series of events within a cell. This series is called signaling and the path that the signal takes is called a pathway. There are many components or elements within a cell that are capable of impacting that signal. These elements can play the role of handing the signal off to another element or they could somehow be an element that takes into consideration some sort of state… maybe a nutritional state… so they are in a way sensors… and based on what they sense about some state decide between which fork in the pathway the signal should be transmitted. Some elements amplify the signal. Some elements may inhibit the signal. Some elements play a small role while other play a huge role. The ones that play the huge role often receive the signal and based on that initiate events that will lead to gene transcription. Most elements in a cell aren’t even called upon to play a part in a signaling cascade while some show up repeatedly in many varied contexts. Last but not least an element may be capable of residing in both the cytoplasm and nucleus and based on where it is currently residing activates distinct functions. Maybe if it is in the nucleus it is promoting but if it is in the cytoplasm it is inhibiting the signaling.

Again a pathway is a series of these elements and as a collective they are studied.

IGF-1’s pro-hypertrophy activity primarily emanates from its ability to activate the Phosphoinositide 3-kinase (PI3k)/Akt signaling pathway. The introduction of names for our elements need not confuse. PI3k is an element and so is Akt. The pathway flows fromIGF-1 binding to it’s receptor and triggeringPI3k which transfers the signaling to Akt. Now there are minor elements between these two but they are the major elements and so the pathway is named after them.

Akt is a very important element. It can trigger protein synthesis and at the same time block up-regulation of the key mediators of muscle atrophy – MuRF1 and MAFbx . It triggers protein synthesis more directly by signaling to mTOR.

It does the latter (prevention of atrophy) by preventing FOXO from moving to the nucleus and this has the ultimate effect of blocking the up-regulation of those muscle atrophy elements MuRF1 and MAFbx. MuRF1 and MAFbx cause atrophy by “spray painting” parts of proteins so that proteasomes can locate those areas and degrade the protein.

Under normal growth conditions, FOXOs are inactivated and not required for the survival of cells. Growth factors (such as insulin & IGF-1) inhibit FOXO activation whereas ROS, DNA-damage, energy stress activate it

The point I appeared to be making is that there are some signals through FOXO that I want and some that I may not want. There is no inherent good or bad in inhibiting FOXO. Stopping FOXO from excessively triggering the atrophy of my muscles is good. Stopping FOXO so that things that need to be eliminated aren’t isn’t a good thing.

So back to the main topic… MuRF1 is really good at marking the thick muscle fibers for destruction and so by blocking MuRF1 activation IGF-1 through trigger Akt helps prevent the break down of the thicker parts of muscle.

IGF-1 may also strongly inhibit the anti-hypertrophy effects of myostatin. Myostatin activates two elements Smad2 and Smad3. It actually binds to a receptor complex made up of ACTRII and ALK4 or ALK5 and in so doing activates Smad2 and Smad3. Once activated these two move to the nucleus and from there they are able to inhibit Akt which ends up inhibiting TORC1. This inhibition feeds back and allows myostatin to activate even more Smad2. Akt remember does two things. It promotes protein synthesis through mTOR and it inhibits atrophy. When it does this in myoblast and myotubes this promotes anabolism and muscle mass. When Myostatin inhibits the activation of Akt in myoblasts and myotubes it hinders anabolism and muscle mass. To some extent TGFB may also activate SMAD2 & 3.

Now the signaling pathway Akt/mTOR/p70S6 in addition to increasing protein synthesis also mediates both differentiation in myoblasts and hypertrophy in myotubes…. basically the making and enlarging of muscle. If left to it’s own devices myostatin would cause decreases in the diameters of myotubes.

IGF-1 dominantly blocks the effects of myostatin in myoblasts and myotubes. I didn’t make up the word “dominate” it was used by the authors of Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size, Anne Ulrike Trendelenbur, American Journal of Physiology – Cell Physiology Published 1 June 2009 Vol. 296 no. 6, C1258-C1270 : .Treatment of human myoblasts with myostatin for 24h decreased phosphorylation [i.e. activation] of Akt by up to 50%. In addition to inhibiting Akt, myostatin decreased phosphorylation of p70S6 kinase and the pro-atrophy transcription factor FoxO1, both of which are normally phosphorylated by Akt.However, Akt, p70S6 kinase, and FoxO1 phosphorylation were restored by treatment with IGF-1, indicating that IGF-1/Akt signaling is dominant over myostatin/Smad/Akt inhibition.

The authors also mentioned in partially non-published data that “In addition to restoring Akt phosphorylation, IGF-1 also partially rescues the differentiation of myostatin-treated myoblasts, as determined by measuring fusion index, diameters (data not shown), and CK (Creatine kinase) activity.”

So IGF-1 gets this signaling pathway going by stimulating PI3k/Akt which leads to the elements that can induce protein synthesis. It is a serious over simplification but resistance exercise leads to activation of the PI3k/Akt pathway by directly inducing muscle expression of IGF-1. – DeVol DL,Activation of insulin-like growth factor gene expression during work-induced skeletal muscle growth, Am J Physiol 259:E89–95 1990 & Yan Z, Insulin-like growth factor immunoreactivity increases in muscle after acute eccentric contractions, J Appl Physiol 74:410–414 1993 . This is sufficient to induce hypertrophy in muscle both in vitro – Vandenburgh HH, Insulin and IGF-I induce pronounced hypertrophy of skeletal myofibers in tissue culture, Am J Physiol 260:C475–484 1991and later in vivo – Musaro A, Localized IGF-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle, Nature Genet 27:195–200 2001 & Coleman ME,Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice, J Biol Chem 270:12109–12116 1995

Activation of Akt is sufficient to induce hypertrophy in vivo. In the study cited for this sentence, acute activation of Akt for two to three weeks was found to be sufficient to induce a doubling in the size of skeletal muscle… this increase occurred in the average cross-sectional are of individual muscle fibers brought about by an increase in the TORC1/p70S6K protein synthesis pathways. – Lai K-MV,Conditional activation of Akt in adult skeletal muscle induces rapid hypertrophy, Mol Cell Biol 24:9295–9304 2004.

I should note that although IGF-1 activates mTOR and p70S6k downstream of PI3K/Akt activation, amino acids can activate mTOR directly bringing about a subsequent stimulation of p70S6K activity.

I discuss how important the element eIF2B is to protein synthesis and how GSK3beta blocks eIF2Bs activity. Well if GSK3beta is inhibited there is also enhanced myotube formation and muscle-specific gene expression leading to differentiation.

Although all of this may seem to be a bit much for this post I bring it up only to point out that IGF-1 inhibits GSK3beta which is a different mechanism by which hypertrophy is induced and myoblast differentiation promoted.

To be continued… but I think I have given a sufficient little primer on IGF-1 and intracellular signaling. IGF-1 is anabolic and anti-catabolic. It inhibits myostatin and GSK3beta and promotes both protein synthesis and differentiation.